Vanda Pharmaceuticals Q1 Earnings Call Highlights

Chief Financial Officer Kevin Moran reported Fanapt net product sales of $29.6 million in Q1 2026, up 26% from $23.5 million in Q1 2025, but down 11% from $33.2 million in Q4 2025. Moran attributed the year-over-year increase primarily to higher volume, “partially offset by a decrease in price net of deductions.” The sequential decline versus Q4 was attributed to lower volume and lower price net of deductions, which he said reflected “insurance plan disruptions and deductible resets that are typical in the ...

Vanda Pharmaceuticals Q1 Earnings Call Highlights - Reportify